News | Paragon BioTeck, Inc.

18 Apr

Paragon BioTeck, Inc., Adds Unique Perspective to Scientific Advisory Board

SAN DIEGO, Calif. – Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, announced today that Captain Ed Woodward, former standout Air Force pilot and Tillman Military Scholar will be inducted as an honorary member of the company’s Scientific Advisory Board (SAB) at ASCRS. Woodward currently attends University of South Florida’s (USF) Morsani School of Medicine; he was medically retired from the Air Force after sustaining a traumatic brain injury (TBI) during inflight training.

17 Nov

Paragon BioTeck, Inc., Receives CE Mark Approval on Comfortear® Lacrisolve™ Absorbable Punctum Plug

Punctal Occlusion

PORTLAND, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear® Lacrisolve™ Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.

15 Oct

Paragon BioTeck, Inc., Announces Corporate Citizenship Initiative, ‘Paragon Gives’

Lacrisolve, Paragon Gives, Philanthropy, Press Release, Punctal Occlusion

PORTLAND, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic […]

25 Jun

Paragon BioTeck, Inc., Receives FDA Clearance for Comfortear® Lacrisolve™ Absorbable Punctum Plug

Lacrisolve, Press Release, Punctal Occlusion

PORTLAND, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, […]

09 Apr

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% Readily Available

Phenylephrine, Press Release

PORTLAND, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, […]

08 Oct

Paragon BioTeck, Inc., Signs Exclusive Distribution Agreement with Horus Pharma for ilast®

Horus Pharma, ilast, Lid Hygiene, Press Release

PORTLAND, Ore. — Paragon BioTeck, Inc., today announced that it has signed a distribution agreement with Horus Pharma for rights […]

19 Apr

Paragon BioTeck, Inc., Signs Exclusive License Agreement with Bausch + Lomb for Phenylephrine

Bausch + Lomb, Phenylephrine, Press Release

Recent U.S FDA Approval of Paragon’s NDA Clears the Way for Bausch + Lomb Commercialization TIGARD, Ore. & MADISON, N.J. […]

21 Mar

Paragon BioTeck, Inc. Announces FDA Approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% & 10%

FDA Approval, Phenylephrine, Press Release

TIGARD, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, […]

13 Mar

Paragon BioTeck, Inc., Appoints New U.S. Medical Advisor

Press Release, Scientific Advisory Board

TIGARD, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, […]

15 Dec

Paragon BioTeck, Inc., Sponsors Event to Benefit Developmentally Disabled

Paragon Gives, Philanthropy, Sponsored Events

TIGARD, Ore. — Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, […]

Paragon BioTeck, Inc., Adds Unique Perspective to Scientific Advisory Board

Paragon BioTeck, Inc., Receives CE Mark Approval on Comfortear® Lacrisolve™ Absorbable Punctum Plug

Paragon BioTeck, Inc., Announces Corporate Citizenship Initiative, ‘Paragon Gives’

Paragon BioTeck, Inc., Receives FDA Clearance for Comfortear® Lacrisolve™ Absorbable Punctum Plug

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% Readily Available

Paragon BioTeck, Inc., Signs Exclusive Distribution Agreement with Horus Pharma for ilast®

Paragon BioTeck, Inc., Signs Exclusive License Agreement with Bausch + Lomb for Phenylephrine

Paragon BioTeck, Inc. Announces FDA Approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% & 10%

Paragon BioTeck, Inc., Appoints New U.S. Medical Advisor

Paragon BioTeck, Inc., Sponsors Event to Benefit Developmentally Disabled

RECENT POSTS

Newsletter Sign-Up